Education
About Us
Working with TipRanks
Follow Us
Indivior PLC (INDV)
NASDAQ:INDV
INDV Stock Chart & Stats
$32.72
--
Market closed
$32.72
--
Day’s Range― - ―
52-Week Range$8.64 - $38.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.63M
Market Cap
$4.09B
Enterprise Value$3.86B
Total Cash (Recent Filing)$195.00M
Total Debt (Recent Filing)$61.00M
Price to Earnings (P/E)19.7
Beta0.60
Next Earnings
Apr 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding125,065,240
10 Day Avg. Volume2,020,895
30 Day Avg. Volume1,626,504
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-45.30
Price to Sales (P/S)3.62
P/FCF Ratio-48.23
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue3.11
Enterprise Value/Gross Profit3.88
Enterprise Value/Ebitda12.81
Forecast
1Y Price Target
$43.75Price Target Upside33.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)3.02
Revenue Forecast (FY)$1.15B
Bulls Say, Bears Say
Bulls Say
Financial StrategyAnalyst notes a shift in focus from restructuring and liability resolution toward expanding EBITDA, generating cash, and deploying capital, which could meaningfully improve profitability if commercial execution aligns with targets.
Patent ProtectionPatent protection for SUBLOCADE combined with underpenetration of long-acting injectables provides a durable runway for extended market capture and substantial peak sales opportunity.
Product AdoptionRising new patient starts and a growing number of active prescribers indicate accelerating adoption of SUBLOCADE, supporting higher future sales potential.
Bears Say
Earnings VolatilityReduced reported revenue may pressure earnings and increase volatility in profitability metrics, making operational performance harder to interpret.
Guidance And Investor ConfidenceLower reported revenue from portfolio simplification could prompt downward revisions to growth expectations and dampen investor confidence in the company's near-term outlook.
Reported RevenuePortfolio simplification is expected to reduce reported revenue, creating a headwind to revenue growth.
Indivior News
INDV FAQ
What was Indivior PLC’s price range in the past 12 months?
Indivior PLC lowest stock price was $8.64 and its highest was $38.00 in the past 12 months.
What is Indivior PLC’s market cap?
Indivior PLC’s market cap is $4.09B.
When is Indivior PLC’s upcoming earnings report date?
Indivior PLC’s upcoming earnings report date is Apr 23, 2026 which is in 51 days.
How were Indivior PLC’s earnings last quarter?
Currently, no data Available
Is Indivior PLC overvalued?
According to Wall Street analysts Indivior PLC’s price is currently Undervalued.
Does Indivior PLC pay dividends?
Indivior PLC does not currently pay dividends.
What is Indivior PLC’s EPS estimate?
Indivior PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Indivior PLC have?
Indivior PLC has 125,065,240 shares outstanding.
What happened to Indivior PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Indivior PLC?
Currently, no hedge funds are holding shares in INDV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Indivior Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.75 (33.71% Upside)
$43.75 (33.71% Upside)
Blogger Sentiment
Bullish
INDV Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Very Bullish
Bullish news 88%
Bearish news 13%
Bearish news 13%
Technicals
SMA
Positive
20 days / 200 days
Momentum
268.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.13%
Trailing 12-Months
Company Description
Indivior PLC
Indivior Pharmaceuticals Inc is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in North Chesterfield, VA.
INDV Company Deck
INDV Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple meaningful achievements: record SUBLOCADE and company revenues, strong adjusted EBITDA growth and margin expansion, clear commercial momentum (prescriber and new patient growth), disciplined cost targets, improved cash flow guidance, and a $400 million opportunistic buyback. Offsets include expected U.S. SUBOXONE pressure, rest-of-world optimization impacts, restructuring charges, gross-to-net volatility, reliance on SUBLOCADE for growth, and some R&D and debt-related uncertainties. On balance, the progress, upgraded profitability guidance, and capital deployment flexibility outweigh the risks and challenges discussed.View all INDV earnings summariesINDV Stock 12 Month Forecast
Average Price Target
$43.75
▲(33.71% Upside)
Technical Analysis
Neurocrine
―
Supernus Pharmaceuticals
―
Teva Pharmaceutical
―
Collegium Pharmaceutical
―
Amneal Pharmaceuticals
―
Ownership Overview
Currently, No data available
---